FDA Letter API

Bio-Botanica, Inc./Nature’s Answer, Inc.

Letter data

Company
Bio-Botanica, Inc./Nature’s Answer, Inc.
Recipient
Mr. Frank D’Amelio Jr. | Chief Executive Officer | Bio-Botanica, Inc./Nature’s Answer, Inc. | Nature’s Answer, Inc. | 85 Commerce Dr. | Hauppauge | , | NY | 11788-3943 | United States
Issue date
2022-05-16
Posted date
Not available
FDA office
Office of Human and Animal Food Operations East – Division 1
Subject
Not available
Product
Dietary Supplements
CMS ID
613479
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Bio-Botanica, Inc./Nature’s Answer, Inc. MARCS-CMS 613479 — May 16, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED Product: Dietary Supplements Recipient: Recipient Name Mr. Frank D’Amelio Jr. Recipient Title Chief Executive Officer Bio-Botanica, Inc./Nature’s Answer, Inc. Nature’s Answer, Inc. 85 Commerce Dr. Hauppauge , NY 11788-3943 United States Issuing Office: Office of Human and Animal Food Operations East – Division 1 United States Dear Mr. D’Amelio Jr.: The Food and Drug Administration has completed evaluation of your firm's corrective actions in response to our Warning Letter CMS# 613479, issued on May 5, 2021. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Scott Loughan Acting Director, Compliance Branch Office of Human and Animal Food Operations East Division 1 Content current as of: 05/23/2022 Regulated Product(s) Dietary Supplements